Exocrine gland

Sight Sciences Announces 1,000th TearCare® Customer Installation

Retrieved on: 
목요일, 1월 26, 2023
Cornea, Exocrine gland, Insurance, MD, MGD, Duane syndrome, Trial of the century, AMA, Patient, RCT, FDA, Publishing, American Medical Association, Indian Medical Association, Pharmaceutical industry

MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced today the 1,000th installation of its TearCare® System.

Key Points: 
  • MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced today the 1,000th installation of its TearCare® System.
  • In 2019 Sight Sciences commercialized the TearCare® System with the knowledge that doctors, and patients were seeking improvements beyond those provided by current over the counter, prescription pharmaceutical, or in-office treatments for dry eye.
  • Desired improvements included faster action, enduring results and, in the case of in-office treatment, a price point allowing more practices to equip their offices.
  • Immediately following launch, Sight Sciences took the first step required to obtain access to coverage and payment for dry eye sufferers when the American Medical Association (AMA) granted a temporary procedural code specifically describing the open eye TearCare® procedure.

Global Head And Neck Cancer Therapeutics Market Report 2022: Increasing Demand For Immunotherapy Treatment Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
화요일, 1월 10, 2023
Pharmaceutical, Health, Oncology, Online, Cell, Large-cell lung carcinoma, Route, Nasal cavity, Hospital, Lymphoma, Therapy, Cancer, Neoplasm, Speech, Administration, Targeted therapy, Melanoma, Paranasal sinuses, Neck, Government, DNA, Head and neck cancer, Pharynx, Head, Immune system, Death, Patient, Exocrine gland, Injection (medicine), Pharmacy Council of India, Radiation, Mortality, Pharmacy, Hair loss, Pembrolizumab, Fatality, Market share, Larynx, Vaccine, Pharmaceutical industry, Immunotherapy

Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer.

Key Points: 
  • Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer.
  • Based on the Therapy Type, the Head and Neck Cancer Therapeutics Market is segmented into Chemotherapy, Immunotherapy, and Targeted Therapy.
  • Region-wise, the Head and Neck Cancer Therapeutics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA.
  • The North America segment registered the largest revenue share in the head and neck cancer therapeutics market in 2021.

New Skincare Range Enabling Aman's Unique Luxurious Experiences to be Enjoyed at Home Implemented Through Partnership Between KOSÉ and Aman

Retrieved on: 
수요일, 1월 11, 2023
Government, B2B, Partnership, Milk, Serum, Camellia, Beauty, Skin, Connacht, Exocrine gland, Elasticity, Travel, AQ, Cosmetics, Chūō-ku, UV, OEM, Dry, Paraben, Environment, Silk, Hotel, Marketing

LONDON, Jan. 11, 2023 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku, Tokyo; President & CEO: Kazutoshi Kobayashi) has cooperated with Aman Group SARL,. （Headquarters: Switzerland; CEO: Vlad Doronin） in the development of a new skincare range, Aman Essential Skin (five products) from Aman's lifestyle brand with global reach, Aman Essentials, and has started producing the products under an OEM contract (manufacture of other companies' brand products). The products will be available from January 11, 2023 in 20 countries, including Japan, and will also be used in treatments at Aman Tokyo and other Aman Spas around the world.

Key Points: 
  • LONDON, Jan. 11, 2023 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku, Tokyo; President & CEO: Kazutoshi Kobayashi) has cooperated with Aman Group SARL,.
  • In KOSÉ's medium-to-long-term VISION 2026, we committed to "Evolving into a company with a global presence."
  • Since then, the partnership between the parties has advanced, and Aman Essential Skin will now be launched, with KOSÉ cooperating in the development and contracted as OEM of the products.
  • KOSÉ focuses in its product manufacturing on creating products that are not only safe and reliable, but also always highly effective and provide the ultimate in comfort.

Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry

Retrieved on: 
수요일, 1월 4, 2023
Exocrine gland, SAN, HCP, Optic nerve, Surgical instrument, Duane syndrome, Safety, Diabetic retinopathy, Health, Research, American Academy, Intraocular pressure, Patient, Trabecular meshwork, American Academy of Ophthalmology, American Academy of Neurology, PARK, IOP, Machine Intelligence Research Institute, Glaucoma, FDA, State, Geographic atrophy, Trauma, MD, Data management, American Urological Association, Severe cognitive impairment, Database, Doctor of Philosophy, RWD, MIGS, Quality of life, Surgeon, Catheter, HCPS, Laika (EHR testing framework), Medicine, Eye, IRIS, OMNI, MGD, Physician, Cataract, Pharmaceutical industry, Dentistry, Medical imaging, Medical device, Ophthalmology

SAN FRANCISCO and MENLO PARK Calif., Jan. 4, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data (RWD)—and Sight Sciences, Inc. (NASDAQ: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced a research collaboration designed to provide insights that may lead to improved outcomes for patients with primary open-angle glaucoma (POAG).

Key Points: 
  • Powered by real-world glaucoma data curated from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight), Qdata Glaucoma is the only data module that captures the full, real-world glaucoma patient journey.
  • This fit-for-purpose data module offers curated data for:
    The IRIS Registry is one of the largest specialty society clinical data registries in all of medicine and the first comprehensive eye disease clinical registry in the U.S.
  • Michael Mbagwu, MD, senior medical director for Verana Health says, "Sight Sciences shares our goal of improving outcomes and treatments for people with glaucoma.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQ® population health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata®.

Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals

Retrieved on: 
금요일, 12월 23, 2022
Strategic planning, The Group, C43, Exocrine gland, IQVIA, Dermatology, Patient, GI, U.S. FDA, Digital, Hair loss, Medtronic, Acne, Hyperpigmentation, Marketing, Endoscopy, FDA, Cancer, Inflammation, Practitioner, XETRA, Prescription, Prevalence, Partnership, Pharmacy, Therapy, Degenerative disease, Skin, Physician, Research, Ageing, Food and Drug Administration, Intelligence, Atopic dermatitis, Fine chemical, Pharmaceutical industry, ASEAN

SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: "Acne is a medical condition that affects millions in the ASEAN region.
  • We would like to thank Cosmo for this partnership and their confidence in Hyphens Pharma.
  • Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries.

Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals

Retrieved on: 
금요일, 12월 23, 2022
Strategic planning, The Group, C43, Exocrine gland, IQVIA, Dermatology, Patient, GI, U.S. FDA, Digital, Hair loss, Medtronic, Acne, Hyperpigmentation, Marketing, Endoscopy, FDA, Cancer, Inflammation, Practitioner, XETRA, Prescription, Prevalence, Partnership, Pharmacy, Therapy, Degenerative disease, Skin, Physician, Research, Ageing, Food and Drug Administration, Intelligence, Atopic dermatitis, Fine chemical, Pharmaceutical industry, ASEAN

SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: "Acne is a medical condition that affects millions in the ASEAN region.
  • We would like to thank Cosmo for this partnership and their confidence in Hyphens Pharma.
  • Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries.

Flea, Tick, And Heartworm Products Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
목요일, 12월 22, 2022
EntirelyPets, US, COVID-19, Flea, Animal, Hair, Parasitism, Loneliness, Research, Praziquantel, Dog, Unicharm, Ivermectin, Pyrantel, Exocrine gland, Tick, Skin, Cat, Forecasting, Family, Heart, Growth, Acquisition, Organization, Anthelmintic, Cestoda, Merck, Dermatitis, Eli Lilly and Company, Perrigo, Human, Bayer, Geography, Pet, Dietary supplement, Virbac

The lea, tick, and heartworm products market is expected to reach $3.68 billion in 2026 at a CAGR of 9.4%.

Key Points: 
  • The lea, tick, and heartworm products market is expected to reach $3.68 billion in 2026 at a CAGR of 9.4%.
  • North America was the largest region in the flea, tick, and heartworm products market in 2021.Europe was the second largest region in the flea, tick, and heartworm products market.
  • Product innovation is a key trend gaining popularity in the flea, tick, and heartworm products market.Major companies in the flea, tick, and heartworm products market are advancing in their new technologies and research and developments in the flea, tick, and heartworm products market.
  • The flea, tick, and heartworm products market research report is one of a series of new reports that provides flea, tick, and heartworm products market statistics, including flea, tick, and heartworm products industry global market size, regional shares, competitors with flea, tick, and heartworm products market share, detailed flea, tick, and heartworm products market segments, market trends, and opportunities, and any further data you may need to thrive in the flea, tick, and heartworm products industry.

Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
화요일, 12월 20, 2022
Molecule, Health care, Target, Exocrine gland, History, MRI, Drug, Abdomen, Biopsy, CT, Discovery, Neck, Spinal cord, Oncology, Mall of America, R, News, Medication, Bone pain, Therapy, Movement, Pharmaceutical formulation, Research, Cancer, Pharmaceutical industry, Medical imaging, Surveying, Medical device, Oil, Marketing, Neuroblastoma, Phase II

Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Drugs In Development, 2022, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.
  • - The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Retrieved on: 
금요일, 12월 9, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Therapy, Baozou Big News Events, M. B, Exocrine gland, Selenium disulfide, Military medicine, Veteran, Diagnosis, Visual Science, Corneal ulcers in animals, Patient, Duane syndrome, Classification, Milner, MGS, OIS, Total, M. A, Drug development, Meibomian gland, News, MGD, European Ophthalmic Pathology Society, All rights reserved, Adverse Events, Luchs, Safety, Investigative Ophthalmology & Visual Science, Systematic review, Contact lens, AES, Prevalence, Pharmaceutical industry, Telescopic sight, Medical device, OSDI, Ophthalmology, Azura, Amit Majmudar

It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.

Key Points: 
  • It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
  • The results from Azuras Phase 2b study of AZR-MD-001 0.5% in MGD were presented during the Spotlight on Dry Eye session at OIS XII.
  • The Phase 2b trial was a multi-center, double-masked, vehicle-controlled, parallel group study that evaluated the safety and efficacy of AZR-MD-001 in 245 patients with MGD.
  • Meibomian Gland Dysfunction is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum which can end in gland atrophy.

Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA

Retrieved on: 
월요일, 12월 12, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Cystic fibrosis transmembrane conductance regulator, IND, Disease, Exocrine gland, Lung, Partnership, Death, Liver, Pain, Cell, Multimedia, Clinical trial, Annual report, FASN, Beta thalassemia, HBE, Cystic fibrosis, Security (finance), GI, Food, Woman, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vertex Pharmaceuticals, Pancreas, Medication, LNP, Water, VRTX, Therapy, Inhalation, Outline, Degenerative disease, Sickle cell disease, Patient, Research, Biology, Medicine, RNA transfection, Safety, Genotype, Pharmaceutical industry, Vaccine, Biotechnology, Science, Vertex, Innovation district, CFTR, Moderna

Vertex plans to initiate a single ascending dose clinical trial for VX-522 in people with CF in the coming weeks.

Key Points: 
  • Vertex plans to initiate a single ascending dose clinical trial for VX-522 in people with CF in the coming weeks.
  • (Graphic: Business Wire)
    VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle.
  • Once delivered to the target lung cells, the mRNA is designed to produce functional copies of the CFTR protein.
  • This investigational messenger ribonucleic acid (mRNA) therapy aims to address the underlying cause of cystic fibrosis (CF).